Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Local peripheral opioid effects and expression of opioid genes in the spinal cord and dorsal root ganglia in neuropathic and inflammatory pain

Obara, Ilonaa,1; Parkitna, Jan Rodriguezb,1; Korostynski, Michalb; Makuch, Wiolettaa; Kaminska, Dorotab; Przewlocka, Barbaraa; Przewlocki, Ryszardb,*

doi: 10.1016/j.pain.2008.12.006

ABSTRACT We investigated the efficacy of local intraplantar ( injection of peptide and non-peptide μ-, δ- and κ-opioid receptor agonists in rat models of inflammatory and neuropathic pain. Locally applied agonists dose-dependently reduced formalin-induced flinching of the inflamed paw and induced antiallodynic and antihyperalgesic effects in sciatic nerve ligation-induced neuropathic pain. These effects were mediated by peripheral opioid receptors localized at the side of tissue/nerve injury, as was demonstrated by selective and non-selective opioid receptors antagonists. The ED50 dose range of μ- and κ-agonists required to induce analgesia in neuropathy was much higher than the ED50 for inflammation; moreover, only δ-agonists were effective in the same dose range in both pain models. Additionally, effective antinociception was achieved at a lower dose of peptide, compared to non-peptide, opioids. Such findings support the use of the peripheral administration of opioid peptides, especially δ-agonists, in treating chronic pain. Furthermore, in order to assess whether adaptations in the expression of opioid genes could underlie the clinical observation of reduced opioid effectiveness in neuropathic pain, we analyzed the abundance of opioid transcripts in the spinal cord and dorsal root ganglia (DRG) during the neuropathy and inflammation. Nerve injury down-regulated mRNA for all types of opioid receptors in the DRG, which is predicted to decrease in the synthesis of opioid receptors to possibly account for the reduced effectiveness of locally administered opioids in neuropathy. The obtained results differentiate inflammatory and neuropathic pain and provide a novel insight into the peripheral effectiveness of opioids in both types of pain.

aDepartment of Pain Pharmacology, Institute of Pharmacology PAS, Smetna 12, 31-343 Krakow, Poland

bDepartment of Molecular Neuropharmacology, Institute of Pharmacology PAS, Smetna 12, 31-343 Krakow, Poland

*Corresponding author. Tel.: +48 12 6623218; fax: +48 12 6374500.


1 These authors contributed equally to this work.


Article history:

Received April 9, 2008

Received in revised form October 31, 2008

Accepted December 1, 2008.

© 2009 Lippincott Williams & Wilkins, Inc.
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website